Literature DB >> 2266175

Monoclonal antibody B72.3 in benign breast lesions.

S Soomro1, S Shousha.   

Abstract

It has been suggested that the monoclonal antibody B72.3 may be useful as a diagnostic tool in fine needle aspirates of breast masses because it recognises "tumour associated glycoprotein (TAG)-72". The antigen was sought in paraffin wax sections of 43 normal and benign breast biopsy specimens, using the avidin-biotin complex technique, to assess the extent of its presence in non-malignant tissue. Strong focal staining was seen in 21 (49%) cases. In 29 cases of fibrocystic change staining was present in 17 (59%). All areas of apocrine metaplasia were positive, as well as a few normal ducts and acini and occasional areas of adenosis. Focal positivity was present in five out of 12 foci of ductal epithelial hyperplasia and in three out of seven radial scars. Staining was absent in two areas of lobular hyperplasia, three areas of sclerosing adenosis, and in a focus of lactational change. Focal positivity was also seen in two out of five fibroadenomas and in two out of three intraduct papillomas. Five normal subareolar sections and a section of normal lactating breast were negative. It is concluded that B72.3 monoclonal antibody can show focal reactivity with a variety of normal and benign epithelial mammary structures, and it is doubtful that its use would be of any help in differentiating benign from malignant cells in fine needle aspirates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2266175      PMCID: PMC502979          DOI: 10.1136/jcp.43.12.1026

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

1.  Monoclonal antibody B72.3 as a diagnostic adjunct in fine needle aspirates of breast masses.

Authors:  J Lundy; M Lozowski; Y Mishriki
Journal:  Ann Surg       Date:  1986-04       Impact factor: 12.969

2.  Use of a monoclonal antibody (B72.3) as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens.

Authors:  W W Johnston; C A Szpak; S C Lottich; A Thor; J Schlom
Journal:  Hum Pathol       Date:  1986-05       Impact factor: 3.466

3.  Cancer risk assessment in benign breast biopsies.

Authors:  D L Page
Journal:  Hum Pathol       Date:  1986-09       Impact factor: 3.466

4.  Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3.

Authors:  V G Johnson; J Schlom; A J Paterson; J Bennett; J L Magnani; D Colcher
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

5.  Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3.

Authors:  D G Sheer; J Schlom; H L Cooper
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

6.  Mammary cancer antigen recognized by monoclonal antibody B72.3 in apocrine metaplasia of the human breast.

Authors:  M Castagna; M Nuti; F Squartini
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

7.  Immunohistochemical staining with monoclonal Ab B72.3 in benign and malignant breast disease.

Authors:  F A Tavassoli; M W Jones; R M Majeste; G L Bratthauer; T J O'Leary
Journal:  Am J Surg Pathol       Date:  1990-02       Impact factor: 6.394

8.  A spectrum of monoclonal antibodies reactive with human mammary tumor cells.

Authors:  D Colcher; P H Hand; M Nuti; J Schlom
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

9.  Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.

Authors:  R Muraro; M Kuroki; D Wunderlich; D J Poole; D Colcher; A Thor; J W Greiner; J F Simpson; A Molinolo; P Noguchi
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

10.  Monoclonal antibody B72.3. An adjunct for evaluation of suspicious aspiration biopsy cytology from the breast.

Authors:  T S Kline; J Lundy; M Lozowski
Journal:  Cancer       Date:  1989-06-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.